AR072359A1 - Encapsulacion de agentes biologicamente activos - Google Patents
Encapsulacion de agentes biologicamente activosInfo
- Publication number
- AR072359A1 AR072359A1 ARP090101617A ARP090101617A AR072359A1 AR 072359 A1 AR072359 A1 AR 072359A1 AR P090101617 A ARP090101617 A AR P090101617A AR P090101617 A ARP090101617 A AR P090101617A AR 072359 A1 AR072359 A1 AR 072359A1
- Authority
- AR
- Argentina
- Prior art keywords
- biologically active
- active agent
- encapsulation
- aqueous
- active agents
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Composiciones que comprenden vehículos en forma de partículas que pueden obtenerse por dichos procedimientos y usos de dichas composiciones en un tratamiento. Reivindicacion 1: Un procedimiento para producir un vehículo en forma de partículas que comprende las etapas de: a) disolver polibutilcianoacrilato (PBCA) en un disolvente orgánico para formar una solucion polimérica; b) anadir una solucion acuosa que contiene un agente biologicamente activo a la solucion polimérica para formar una emulsion primaria de gotas de fase acuosa en una fase orgánica continua; c) mezclar la emulsion primaria con un medio acuoso para formar una emulsion secundaria; y d) permitir que la fase orgánica se evapore y por lo tanto obtener vehículos en forma de partículas que comprende una luz hueca que contiene el agente biologicamente activo en una fase acuosa. Reivindicacion 6: El procedimiento de una cualquiera de las reivindicaciones 1 a 4, en el que el vehículo en forma de partículas es una nanopartícula. Reivindicacion 7: El procedimiento de una cualquiera de las reivindicaciones 1 a 6, en el que el agente biologicamente activo es una proteína o péptido.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5077508P | 2008-05-06 | 2008-05-06 | |
US7417108P | 2008-06-20 | 2008-06-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR072359A1 true AR072359A1 (es) | 2010-08-25 |
Family
ID=40944671
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090101618A AR071634A1 (es) | 2008-05-06 | 2009-05-05 | Nanoparticulas para encapsulacion de agentes biologicamente activos |
ARP090101616A AR071633A1 (es) | 2008-05-06 | 2009-05-05 | Encapsulacion de agentes biologicamente activos |
ARP090101619A AR072668A1 (es) | 2008-05-06 | 2009-05-05 | Encapsulacion de agentes biologicamente activos |
ARP090101617A AR072359A1 (es) | 2008-05-06 | 2009-05-05 | Encapsulacion de agentes biologicamente activos |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090101618A AR071634A1 (es) | 2008-05-06 | 2009-05-05 | Nanoparticulas para encapsulacion de agentes biologicamente activos |
ARP090101616A AR071633A1 (es) | 2008-05-06 | 2009-05-05 | Encapsulacion de agentes biologicamente activos |
ARP090101619A AR072668A1 (es) | 2008-05-06 | 2009-05-05 | Encapsulacion de agentes biologicamente activos |
Country Status (11)
Country | Link |
---|---|
US (1) | US20110064821A1 (es) |
EP (2) | EP2271323A2 (es) |
JP (1) | JP2011522792A (es) |
KR (3) | KR20110010758A (es) |
AR (4) | AR071634A1 (es) |
CA (1) | CA2721241A1 (es) |
CL (4) | CL2009001076A1 (es) |
PE (4) | PE20091882A1 (es) |
TW (4) | TW201006495A (es) |
UY (4) | UY31808A (es) |
WO (1) | WO2009135853A2 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2721307A1 (en) * | 2008-05-06 | 2009-11-12 | Glaxo Group Limited | Encapsulation of biologically active agents |
US9504759B2 (en) | 2011-08-11 | 2016-11-29 | Bar-Ilan University | Surface modified proteinaceous spherical particles and uses thereof |
US10112988B2 (en) | 2012-01-09 | 2018-10-30 | Icb International, Inc. | Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide |
US10112987B2 (en) * | 2012-01-09 | 2018-10-30 | Icb International, Inc. | Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide |
JP6612333B2 (ja) * | 2014-05-30 | 2019-11-27 | アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー | 高薬物負荷ポリ(アルキル2−シアノアクリレート)ナノカプセル |
CA2946810A1 (en) * | 2014-05-30 | 2015-12-03 | AbbVie Deutschland GmbH & Co. KG | Nanoencapsulation of antigen-binding molecules |
EP3154524B1 (en) * | 2014-06-12 | 2021-12-15 | Adare Pharmaceuticals USA, Inc. | Extended-release drug delivery compositions |
EP3160449B1 (en) | 2014-06-24 | 2023-12-13 | The Trustees of Princeton University | Process for encapsulating soluble biologics, therapeutics, and imaging agents |
WO2019055539A1 (en) | 2017-09-12 | 2019-03-21 | Prudhomme Robert K | CELLULOSIC POLYMER NANOPARTICLES AND METHODS OF FORMING THE SAME |
US11731099B2 (en) | 2018-07-20 | 2023-08-22 | The Trustees Of Princeton University | Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation |
US20220031630A1 (en) * | 2018-09-13 | 2022-02-03 | The Brigham And Women's Hospital, Inc. | Nanoparticle formulations and methods of their use |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4833666A (en) | 1986-12-24 | 1989-05-23 | U.S. Philips Corporation | Disc-record player suitable for scanning disc of different types |
FR2649321A1 (fr) * | 1989-07-07 | 1991-01-11 | Inst Nat Sante Rech Med | Compositions a base de derives nucleotidiques, leurs procedes de preparation, et leurs utilisations notamment en tant que compositions pharmaceutiques |
FR2659554B1 (fr) * | 1990-03-16 | 1994-09-30 | Oreal | Composition pour le traitement cosmetique et/ou pharmaceutique des couches superieures de l'epiderme par application topique sur la peau et procede de preparation correspondant. |
EP0683667A1 (en) * | 1993-02-15 | 1995-11-29 | Shield Research Limited | Polyalkylcyanoacrylate nanocapsules |
CA2171303C (en) * | 1993-09-09 | 2006-06-06 | Werner Weitschies | Active principles and gas containing microparticles |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
GB9809839D0 (en) | 1998-05-09 | 1998-07-08 | Glaxo Group Ltd | Antibody |
IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US20030152636A1 (en) * | 2000-02-23 | 2003-08-14 | Nanopharm Ag | Method of treating cancer |
US7417130B2 (en) | 2000-09-08 | 2008-08-26 | University Of Zurich | Collection of repeat proteins comprising repeat modules |
WO2003005952A2 (en) * | 2001-07-10 | 2003-01-23 | Corixa Corporation | Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres |
AR040778A1 (es) | 2002-08-06 | 2005-04-20 | Glaxo Group Ltd | Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina). |
JP4871126B2 (ja) | 2003-07-04 | 2012-02-08 | アフィボディ・アーベー | Her2に対する結合親和性を有するポリペプチド |
AU2003275958A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
WO2005056764A2 (en) | 2003-12-05 | 2005-06-23 | Compound Therapeutics, Inc. | Inhibitors of type 2 vascular endothelial growth factor receptors |
JP2008513363A (ja) | 2004-09-14 | 2008-05-01 | ナノデル テクノロジーズ ゲーエムベーハー | ナノ粒子を含む送達媒体 |
GB0525662D0 (en) | 2005-12-16 | 2006-01-25 | Glaxo Group Ltd | Immunoglobulins |
PL2177536T3 (pl) | 2006-03-30 | 2014-11-28 | Glaxo Group Ltd | Przeciwciała przeciwko peptydowi beta-amyloidu |
EP1958957A1 (en) | 2007-02-16 | 2008-08-20 | NascaCell Technologies AG | Polypeptide comprising a knottin protein moiety |
US8877186B2 (en) | 2007-06-06 | 2014-11-04 | Domantis Limited | Polypeptides, antibody variable domains and antagonists |
GB0724331D0 (en) | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
-
2009
- 2009-05-05 EP EP09742071A patent/EP2271323A2/en not_active Withdrawn
- 2009-05-05 JP JP2011507897A patent/JP2011522792A/ja active Pending
- 2009-05-05 PE PE2009000606A patent/PE20091882A1/es not_active Application Discontinuation
- 2009-05-05 PE PE2009000609A patent/PE20091965A1/es not_active Application Discontinuation
- 2009-05-05 TW TW098114867A patent/TW201006495A/zh unknown
- 2009-05-05 AR ARP090101618A patent/AR071634A1/es not_active Application Discontinuation
- 2009-05-05 UY UY0001031808A patent/UY31808A/es unknown
- 2009-05-05 PE PE2009000608A patent/PE20091964A1/es not_active Application Discontinuation
- 2009-05-05 CA CA2721241A patent/CA2721241A1/en not_active Abandoned
- 2009-05-05 TW TW098114865A patent/TW201012490A/zh unknown
- 2009-05-05 WO PCT/EP2009/055436 patent/WO2009135853A2/en active Application Filing
- 2009-05-05 AR ARP090101616A patent/AR071633A1/es not_active Application Discontinuation
- 2009-05-05 KR KR1020107027240A patent/KR20110010758A/ko not_active Application Discontinuation
- 2009-05-05 KR KR1020107027449A patent/KR20110010760A/ko not_active Application Discontinuation
- 2009-05-05 UY UY0001031810A patent/UY31810A/es unknown
- 2009-05-05 TW TW098114853A patent/TW201012489A/zh unknown
- 2009-05-05 PE PE2009000607A patent/PE20091829A1/es not_active Application Discontinuation
- 2009-05-05 US US12/991,556 patent/US20110064821A1/en not_active Abandoned
- 2009-05-05 EP EP11192165A patent/EP2441447A1/en not_active Withdrawn
- 2009-05-05 CL CL2009001076A patent/CL2009001076A1/es unknown
- 2009-05-05 UY UY0001031809A patent/UY31809A/es unknown
- 2009-05-05 CL CL2009001081A patent/CL2009001081A1/es unknown
- 2009-05-05 AR ARP090101619A patent/AR072668A1/es not_active Application Discontinuation
- 2009-05-05 KR KR1020107027425A patent/KR20110015604A/ko not_active Application Discontinuation
- 2009-05-05 CL CL2009001080A patent/CL2009001080A1/es unknown
- 2009-05-05 UY UY0001031807A patent/UY31807A/es unknown
- 2009-05-05 AR ARP090101617A patent/AR072359A1/es not_active Application Discontinuation
- 2009-05-05 CL CL2009001077A patent/CL2009001077A1/es unknown
- 2009-05-05 TW TW098114851A patent/TW201012488A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CL2009001076A1 (es) | 2010-09-24 |
TW201012488A (en) | 2010-04-01 |
US20110064821A1 (en) | 2011-03-17 |
KR20110010758A (ko) | 2011-02-07 |
AR071634A1 (es) | 2010-06-30 |
AR071633A1 (es) | 2010-06-30 |
CA2721241A1 (en) | 2009-11-12 |
JP2011522792A (ja) | 2011-08-04 |
PE20091829A1 (es) | 2009-12-12 |
UY31809A (es) | 2009-12-14 |
PE20091965A1 (es) | 2010-01-09 |
EP2271323A2 (en) | 2011-01-12 |
CL2009001077A1 (es) | 2010-09-24 |
KR20110010760A (ko) | 2011-02-07 |
PE20091882A1 (es) | 2009-12-24 |
TW201012490A (en) | 2010-04-01 |
UY31810A (es) | 2009-12-14 |
WO2009135853A3 (en) | 2011-05-12 |
AR072668A1 (es) | 2010-09-15 |
CL2009001080A1 (es) | 2010-09-24 |
CL2009001081A1 (es) | 2010-09-24 |
TW201012489A (en) | 2010-04-01 |
UY31808A (es) | 2009-12-14 |
WO2009135853A2 (en) | 2009-11-12 |
PE20091964A1 (es) | 2010-01-09 |
TW201006495A (en) | 2010-02-16 |
EP2441447A1 (en) | 2012-04-18 |
KR20110015604A (ko) | 2011-02-16 |
UY31807A (es) | 2009-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR072359A1 (es) | Encapsulacion de agentes biologicamente activos | |
PE20191714A1 (es) | Nanoparticula polimerica de finasterida y minoxidil, proceso de preparacion, suspension acuosa conteniendo la misma, composicion farmaceutica, y su uso | |
AR092402A1 (es) | Nanoparticula polimerica de finasterida, suspension acuosa conteniendo a la misma, composicion para tratamiento de alopecia, proceso de preparacion de dicha composicion, y su uso | |
CO2019005729A2 (es) | Preparación de complejos sólidos de ciclodextrina para suministro de ingredientes farmacéuticos activos oftálmicos | |
PE20050926A1 (es) | Composicion y forma de dosificacion que comprende una molecula anfifilica como un vehiculo de suspension | |
BRPI0518677A2 (pt) | produto sàlido, processos para a produÇço de um produto sàlido e para a produÇço de uma nanodispersço estabilizada ou micela carregada, lÍquido translécido, mÉtodo de tratamento mÉdico, e, dispositivo para a produÇço de formulaÇÕes sàlidas de agentes biologicamente ativos lÍquidos | |
AR071239A1 (es) | Microesferas que tienen una estructura de nucleo / recubrimiento que comprenden aripiprazol y uso | |
PE20080738A1 (es) | Sistema de liberacion controlada y metodo para fabricarlo | |
CL2007003730A1 (es) | Nanoemulsion que comprende a) componente acuoso y b) un vehiculo con i) 0,1-15% de un componente lipofilico, ii) un tensoactivo y iii) un alcohol c3-c5; composicion que la comprende opcionalmente con un agente activo; proceso de preparacion de la nanoemulsion y de la composicion; kit; y uso para diagnosticar enfermedades dermicas y proliferativas, y tratar enfermedades virales, dermicas y proliferativas. | |
AR072685A1 (es) | Composicion topica para el tratamiento de queratosis actinica | |
BRPI0913326C1 (pt) | formulação farmacêuticas tópicas contendo uma baixa concentração de peróxido de benzoíla em suspensão aquosa e um solvente orgânico miscível em água | |
CL2011002053A1 (es) | Composicion farmaceutica de espuma en aerosol en emulsion de aceite en agua que comprende un agente farmaceuticamente activo, agua, aceite, disolvente organico, componente tensoactivo, y propulsor; procedimiento de preparacion; uso para tratar enfermedades, o afecciones de la piel. | |
PE20080765A1 (es) | Formas de dosificacion farmaceutica | |
AR086115A1 (es) | Formulaciones parenterales mejoradas de agentes farmaceuticos lipofilos y los metodos para la preparacion y el uso de las mismas | |
UY30587A1 (es) | Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasa s janus | |
BR112015022985A2 (pt) | Microesferas de buprenorfina de carga de fármaco alta e método para produção das mesmas | |
AR077155A1 (es) | Nanodispersion, nanoparticulas y solucion | |
AR085181A1 (es) | Composicion para el cuidado del cabello, metodo de elaboracion de la composicion, uso | |
CO6311052A2 (es) | Una microemulsion que comprende un ingrediente activo, un solvente y un surfactante no ionico y proceso para su preparación | |
AR072921A1 (es) | Mejoras relacionadas con composiciones que contienen agentes tensioactivos | |
AR087911A1 (es) | Metodos en multiples etapas y composiciones para desensibilizar las caras de formaciones subterraneas | |
AR094291A1 (es) | Formulacion inyectable de liberacion prolongada que comprende tolvaptan opticamente activo, y un procedimiento para producirla | |
ES2625873T3 (es) | Método de preparación de micropartículas biodegradables que contienen fármacos | |
AR065564A1 (es) | Composiciones farmaceuticas que comprenden un agente calciletico | |
AR064104A1 (es) | Formas de dosificacion en microemulsion de valsartan, y metodos para elaborarlas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |